As of 2024-12-13, the EV/EBITDA ratio of Trillium Therapeutics Inc (TRIL.TO) is -43.28. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. TRIL.TO's latest enterprise value is 2,475.02 mil CAD. TRIL.TO's TTM EBITDA according to its financial statements is -57.19 mil CAD. Dividing these 2 quantities gives us the above TRIL.TO EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | - | - |
| Forward P/E multiples | - | - |
| Fair Price | - | - |
| Upside | - | - |
| Date | EV/EBITDA |